Duchenne's Muscular Dystrophy (DMD) Approved for Marketing Phase Trials for Deflazacort (DB11921)

Also known as: Duchenne's Muscular Dystrophy / Duchenne Muscular Dystrophy (DMD) / Duchenne Muscular Dystrophy / Muscular Dystrophy, Duchenne / Muscular dystrophy

IndicationStatusPhase
DBCOND0066749 (Duchenne's Muscular Dystrophy (DMD))Approved for MarketingNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02592941Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy